A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)

Sponsor
GlaxoSmithKline
Study ID
NCT07108270
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Neoplasms, Endometrial

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dostarlimab — BIOLOGICAL
    Dostarlimab will be administered.
  • Carboplatin — DRUG
    Carboplatin will be administered.
  • Paclitaxel — DRUG
    Paclitaxel will be administered.

Study Details

The goal of this clinical trial is to see how well dostarlimab works when administered with the chemotherapy drugs carboplatin and paclitaxelin in treating EC in Chinese participants. The study aims to understand the treatments effectiveness, safety, how the drugs behave in the body, and whether it causes any immune reactions.

Key Dates

Start date
Nov 27, 2025
Status verified
Dec 2025
Primary completion
Mar 31, 2030
Completion
Mar 31, 2030

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Dostarlimab-Carboplatin-Paclitaxel followed by Dostarlimab Monotherapy

Primary Outcome Measure

Durable Response Rate for 12 months (DRR12) assessed by Blinded Independent Central Review (BICR) [ Time Frame: Up to approximately 148 weeks ]

Central Contacts